参考文献/References:
[1] Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterolog-ous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia [J]. Lancet, 2021, 397(10275): 671-681.
[2] Alturki SO, Alturki SO, Connors J, et al. The 2020 pande-mic: current SARS-CoV-2 vaccine development [J]. Front Immunol, 2020, 11: 1880.
[3] Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of rAd26 and rAd5 vector-based heterolog-ous prime-boost COVID-19 vaccine in two formulations:two open, non-randomised phase 1/2 studies from Russia [J]. Lancet, 2020, 396(10255): 887-897.
[4] Wang FZ, Kream RM, Stefano GB. An evidence based per-spective on mRNA-SARS-CoV-2 vaccine development [J].Med Sci Monit, 2020, 26: e924700.
[5] Dong YT, Dai T, Wei YJ, et al. A systematic review of SARS-CoV-2 vaccine candidates [J]. Signal TransductTarget Ther, 2020, 5(1): 237-251.
[6] Jeyanathan M, Afkhami S, Smaill F, et al. Immunological considerations for COVID-19 vaccine strategies [J]. NatRev Immunol, 2020, 20(10): 615-632.
[7] Dagotto G, Yu JY, Barouch DH. Approaches and challenges in SARS-CoV-2 vaccine development [J]. Cell HostMicrobe, 2020, 28(3): 364-370.
[8] Barajas-Nava LA. Development of SARS-CoV-2 vaccines [J]. Bol Med Hosp Infant Mex, 2021, 78(1): 66-74.
[9] Sathian B, Asim M, Banerjee I, et al. Development andimplementation of a potential coronavirus disease 2019(COVID-19) vaccine: a systematic review and meta-analy-sis of vaccine clinical trials [J]. Nepal J Epidemiol, 2021, 11(1): 959-982.
[10] Sahin U, Muik A, Derhovanessian E, et al. COVID-19vaccine BNT162b1 elicits human antibody and Th1 T cell responses [J]. Nature, 2020, 586(7830): 594-599.
[11] Chauhan N, Soni S, Gupta A, et al. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: a systematic review [J]. J Med Virol,2020, 93(4): 1967-1982.
[12] Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of BNT162b2 mRNA COVID-19 vaccine [J]. N Engl J Med,2020, 383(27): 2603-2615.
[13] Baden LR, EISahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine [J]. N Engl JMed, 2021, 384(5): 403-416.
[14] Zhao J, Zhao S, Ou JX, et al. COVID-19: coronavirusvaccine development updates [J]. Front Immunol, 2020, 11:602256.
[15] Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, andimmunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation,open-label,non- randomised, first-in-human trial [J]. Lancet, 2020,395(10240): 1845-1854.
[16] Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immuno-genicity of the chAdOxi nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase1/2, single-blind, randomized controlled trial [J]. Lancet, 2020, 396(10249):467-478.
[17] Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26. CoV2.S vaccine against CoV-19 [J]. NEngl J Med, 2021, 10: 1056.
[18] Mahase E. Novavax vaccine efficacy is 86% against UKvariant and 60% against South African variant [J]. BMJ，2021, 372: n296.
[19] Post N, Eddy D, Huntley C, et al. Antibody response to SARS-CoV-2 infection in humans: a systematic review [J].PLOS ONE, 2020, 15(2): e0244126.
[20] Kaur RJ, Dutta S, Bhardwaj P, et al. Adverse eventsreported from COVID-19 vaccine trials: a systematic review [J]. Ind J Clin Biochem, 2021, 3: 1-13.
[21] Rojas-Perez-Ezquerra P, Crespo Ouiros J, Tornero Molina P, et al. Safety of new mRNA vaccines against COVID-19 in severely allergic patients [J]. J Investig Allergol ClinImmunol, 2021, 31(2): 180-181.
[22] 姜 辉，李 娟，罗俊华. 不同炎症性评分指标对COVID-19普通型转重型的评估价值[J]. 华南国防医学杂志，2020，34（9）：661-665.
[23] Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-weekimmunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment:preliminary data from a single institution [J]. J HematolOncol, 2021, 14(1): 81-93.
[24] Weissman D, Alameh MG, Silva T, et al. D614G spikemutation increases SARS-CoV-2 susceptibility to neutra-lization [J]. Cell Host Microbe, 2021, 29(1): 23-31.
[25] Anderson EJ, Rouphael NG, Widge AT, et al. Safety andimmunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults [J]. N Engl J Med, 2020, 383(25): 2427-2438.
[26] Emary KRW, Golubchik T, Aley PK, et al. Efficacy ofchAdOxi nCoV-19(AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01(B.1.1.7): an exploratory analysis of a randomized controlled trial [J]. Lancet, 2021,397(10282): 1351-1362.
[27] Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant [J]. N Engl J Med, 2021, 384(20): 1899-1909.
[28] Madhi SA, Baillie V, Cutland CL, et al. Efficacy of chAdOxi nCoV-19 vaccine against the B.1.351 variant [J]. N Engl JMed, 2021, 384(20): 1885-1898.
[29] Gobbi F, Buonfrate D, Moro L, et al. Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection [J]. Viruses, 2021, 13(2): 422.
相似文献/References:
[1]汪志忠 别毕洲 陈迎春 盛柳青 李欢欢 游慧超 叶建锋 李 俊.新型冠状病毒肺炎疫情期间诊治神经重症合并肺部病变10例报道[J].中国临床神经外科杂志,2020,(03):186.[doi:10.13798/j.issn.1009-153X.2020.03.022]
[2]冯娟娟 张 纯 郑 婷 方 艳 赵 畅 王昭艳 张 青 叶建锋 陈迎春 李欢欢.颅内动脉瘤合并新型冠状病毒肺炎的围手术期护理及医护人员防护[J].中国临床神经外科杂志,2020,(04):241.[doi:10.13798/j.issn.1009-153X.2020.04.017]
[3]湖北省脑血管病防治学会.新型冠状病毒肺炎防疫期间湖北省脑卒中绿色通道管理[J].中国临床神经外科杂志,2020,(04):254.[doi:10.13798/j.issn.1009-153X.2020.04.022]
[4]潘 力 温健鹏 黄 河 秦 杰 赵曰圆 沈春发 闫林海 石 纪 向伟楚 杨 铭 马廉亭.新型冠状病毒肺炎高风险地区出血性卒中的治疗对策[J].中国临床神经外科杂志,2020,(05):268.[doi:10.13798/j.issn.1009-153X.2020.05.004]
PAN Li,WEN Jian-peng,HUANG He,et al.Treatment strategies for hemorrhagic stroke in high-risk areas of Corona Virus Disease 2019[J].,2020,(07):268.[doi:10.13798/j.issn.1009-153X.2020.05.004]
[5]袁 波 蔡 新 王建春 胡小鹏 李志文 卢 婷 安亚文.新型冠状病毒肺炎病人康复早期心理应激状态调查及影响因素分析[J].中国临床神经外科杂志,2020,(08):531.[doi:10.13798/j.issn.1009-153X.2020.08.011]
YUAN Bo,CAI Xin,WANG Jian-chun,et al.Investigation of psychological stress state of during early convalescence of patients with coronavirus disease 2019 and analysis of its influencing factors[J].,2020,(07):531.[doi:10.13798/j.issn.1009-153X.2020.08.011]
[6]苏晓娟 华 莎.抗疫护理团队参与新型冠状病毒肺炎重症监护病区组建和运行的思考[J].中国临床神经外科杂志,2020,(08):557.[doi:10.13798/j.issn.1009-153X.2020.08.020]
[7]李 炳 汪 欢 余 鹏 王羡科.新型冠状病毒肺炎期间神经外科医护人员职业暴露的相关因素分析[J].中国临床神经外科杂志,2020,(09):590.[doi:10.13798/j.issn.1009-153X.2020.09.005]
LI Bing,WANG Huan,YU Peng,et al.Analysis of related factors of occupational exposure of medical staff in our department during COVID-19 epidemic based on DEMATEL method[J].,2020,(07):590.[doi:10.13798/j.issn.1009-153X.2020.09.005]
[8]陶 祥 张文斐 刘骏辉 朱晓楠 冀保卫 张 戈 徐海涛 陈治标.新型冠状病毒性肺炎疫情下神经外科急诊诊疗行为的建议及策略[J].中国临床神经外科杂志,2020,(09):594.[doi:10.13798/j.issn.1009-153X.2020.09.006]
TAO Xiang,ZHANG Wen-fei,LIU Jun-hui,et al.Strategies and suggestions for emergency diagnosis and treatment of neurosurgery during coronavirus disease 2019 epidemic[J].,2020,(07):594.[doi:10.13798/j.issn.1009-153X.2020.09.006]
[9]詹昱新 李素云 韩克霞等.综合医院神经外科应对新型冠状病毒肺炎的护理应急管理[J].中国临床神经外科杂志,2021,26(03):206.[doi:10.13798/j.issn.1009-153X.2021.03.023]
[10]黄 娜 乐革芬 欧阳燕等.一级响应常态化防控下神经外科病房护理管理[J].中国临床神经外科杂志,2021,26(03):209.[doi:10.13798/j.issn.1009-153X.2021.03.024]